Camurus company profile

CAMX · Nasdaq Stockholm · SEK

Compare Camurus
kr 739.50Change from previous close: −0.07%Absolute change: −kr 0.50

Close · November 20, 2026

Company profile

Camurus has 323 employees and is headquartered in Lund, Sweden.

Based in Lund, Sweden, Camurus was founded in 1991 and works as a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases. Its marketed products include Buvidal, used for opioid dependence and chronic pain, and Brixadi, used for opioid use disorder. The pipeline covers chronic pain, acromegaly, prostate cancer, polycystic liver disease and rare genetic obesity disorders, with partnerships involving Braeburn Pharmaceuticals, Rhythm Pharmaceuticals and Eli Lilly. The company serves customers in Europe, Africa, the Middle East, North America and Asia.

In the fiscal year ended December 2025, revenue reached SEK 2.3 billion, an increase of 21.3% on the previous year, and net profit amounted to SEK 735.6 million. The company had 323 employees and its headquarters are in Lund, Sweden. All amounts are stated in Swedish kronor (SEK).

Company facts

Industry
Biotechnology
Country
Sweden
Headquarters
Rydbergs torg 4, 224 84, Lund
Employees
323
Chief executive
Fredrik Tiberg
Founded
1991
Fiscal year
January - December
Listing
CAMX · Nasdaq Stockholm
Currency
SEK
ISIN
SE0007692850

Camurus and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
CamurusCAMXSweden$4.32B32337.4%58.7
ABIVAXABVXFrance$6.06B98-6,270.4%—
Bachem HoldingBANBSwitzerland$6.84B2,72521.8%38.7
Bavarian NordicBAVADenmark$2.72B1,92318.1%12.7
BioArcticBIOA.BSweden$2.66B15019.6%259.5
ALK-AbellóALK.BDenmark$7.79B2,79526.6%38.0

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Camurus with its competitors